Kissei Lowers Tavneos Sales Outlook Following Safety and Data Integrity Concerns

Kissei Pharmaceutical has significantly reduced its sales forecast for Tavneos (avacopan) for fiscal year 2026. This adjustment follows new patient start restrictions due to a rapid safety communication and ongoing concerns regarding the integrity of the drug's clinical trial data. Issues include a retracted paper by The New England Journal of Medicine and an EU panel's recommendation to withdraw approval, impacting the drug's market presence and patient access.